U.S. International Reference Pricing: Global Implications and Pharma Strategy
Unintended global fallout of international reference pricing: How the U.S. Most Favored Nation policy could…
Certara2025 年 10 月 6 日
Highlights from the FDA Guidance on Dosage Optimization for Therapeutic Radiopharmaceuticals
Learn how radiopharmaceutical therapies work in oncology and how Certara supports development with modeling, simulation,…
Certara2025 年 10 月 3 日
How Certara and TrialAssure Partner to Deliver Faster, Compliant Anonymization for Global Sponsors
Discover how Certara's partnership with TrialAssure provides global sponsors with accelerated, compliant, and enhanced document…
Certara2025 年 10 月 3 日
Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer
Certara’s support enabled fast-track FDA oncology approval 2025 for Sunvozertinib, a breakthrough NSCLC therapy targeting…
Certara2025 年 10 月 2 日
Preparing for the Operational Burden of OS Requirements in Oncology Trials
Ananth Kadambi outlines how clinical operations teams can plan for FDA’s OS requirements—enhancing patient tracking…
Certara2025 年 9 月 26 日
How RWE and Predictive Modeling Support OS-Focused Trial Designs
Discover how real-world evidence and predictive modeling strengthen OS-focused trial designs in oncology, improving efficiency…
Certara2025 年 9 月 25 日
Using Model-Informed Drug Development to Support OS Endpoints
Ananth Kadambi shares how model-informed drug development helps sponsors predict efficacy and align shorter oncology…
Certara2025 年 9 月 24 日
How FDA’s Focus on Overall Survival Redefines Trial Success
Ananth Kadambi explains how FDA’s emphasis on overall survival reshapes oncology drug trial success metrics…
Certara2025 年 9 月 23 日
